Coeptis Therapeutics Holdings Inc. Common Stock (COEP) Stock Price

COEPStock
$5.50−45.29%52W
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta0.58

COEP Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-76.76%
Price vs S&P 500 (4W)83.96%
VGM Score17.52

COEP Analyst Recommendations

Nov 2024
Dec 2024
Jan 2025
Feb 2025
2.17
2.17
2.17
2.17

Industry Peers — Finance Services(179)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/E Ratio (Annual)ROE (TTM)Operating Margin (TTM)Revenue Growth (5Y)Price
COEPCoeptis Therapeutics Holdings Inc. Common Stock
F—D—-641.1%-945.3%—$5.50
AXPAmerican Express CompanyDBB19.5x34.1%18.2%16.0%$313.59
NUNu Holdings Ltd.DBB24.5x30.3%22.7%84.5%$14.56
MSTRStrategy Inc Common Stock Class ADDB—-60.8%-7272.5%-0.1%$136.83
COINCoinbase Global, Inc. Class A Common StockDCB36.2x-6.9%9.9%41.2%$173.16
SYFSYNCHRONY FINANCIALBCB6.7x20.9%18.4%0.9%$73.68
CRCLCircle Internet Group, Inc.DCB126.1x13.6%7.4%—$82.22
SOFISoFi Technologies, Inc. Common StockDBC39.0x6.2%-19.9%—$14.55
BMNRBitMine Immersion Technologies, Inc.DAB37.5x-84.6%-14505.1%428.4%$21.66
CHYMChime Financial, Inc. Class A Common StockDAA—-1.3%-2.1%—$29.67
IRENIREN Limited Ordinary SharesDBD183.7x-23.0%-163.9%145.7%$26.99

About Coeptis Therapeutics Holdings Inc. Common Stock

Coeptis Therapeutics develops cell therapy platforms for cancer patients. The company's pipeline includes SNAP-CAR, a multi-antigen CAR T technology licensed from the University of Pittsburgh, and CD38-GEAR-NK, a cell therapy candidate, along with a companion diagnostic. Coeptis collaborates with VyGen-Bio and the Karolinska Institutet on its CD38-targeted oncology programs.